Abstract
Drug allergy refers to a hypersensitivity reaction for which either an IgE or T-cell-mediated mechanism is demonstrated. The recognition of the drug by B and T cells is influenced by variants of HLA genes. The genetic factors involved in IgE-mediated mechanisms have been studied mainly in β-lactam reactions, and they appear to be related to human leukocyte antigen presentation (HLA A2 and DRw52), TNFA – 308G > A, class switching to IgE by B cells (variants of IL-13 and of IL-4RA), and expression of IgE receptors on target cells (variant of the FcηRIβ gene). Delayed Tcell- mediated reactions are also associated with HLA alleles. Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity. HLA-B*5701 seems to be a strong predictor in whites, but not in Hispanics or Africans. Carbamazepine hypersensitivity is also influenced by gene variants of cytochrome P450 enzymes on the generation of reactive metabolites, while CYP2C9*2 and CYP2C9*3 polymorphisms influence the bioactivation of sulfamethoxazole in prohapten. Pharmacogenetic studies on aspirin hypersensitivity have identified distinct types of predictors, such as HLA genotypes, a polymorphism in the promoter of the FcηRIα gene, and variants in genes of enzymes from the arachidonic acid pathway. In the future, identification of genetic predictors will benefit from genomewide association studies that also take ethnic differences into account. Ideally, predictors will help to prevent adverse reactions, as suggested by a recent study on the effectiveness of prospective HLA-B* 5701 screening to prevent hypersensitivity reactions to abacavir in HIV patients.
Keywords: Pharmacogenetics, gene polymorphism, drug hypersensitivity, drug allergy, β-lactams, aspirin, sulfamethoxazole, abacavir
Current Pharmaceutical Design
Title: Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity
Volume: 14 Issue: 27
Author(s): J. L. Gueant, R. M. Gueant-Rodriguez, I. Aimone Gastin, J. A. Cornejo-Garcia, M. Viola, A. Barbaud, P. M. Mertes, M. Blanca and A. Romano
Affiliation:
Keywords: Pharmacogenetics, gene polymorphism, drug hypersensitivity, drug allergy, β-lactams, aspirin, sulfamethoxazole, abacavir
Abstract: Drug allergy refers to a hypersensitivity reaction for which either an IgE or T-cell-mediated mechanism is demonstrated. The recognition of the drug by B and T cells is influenced by variants of HLA genes. The genetic factors involved in IgE-mediated mechanisms have been studied mainly in β-lactam reactions, and they appear to be related to human leukocyte antigen presentation (HLA A2 and DRw52), TNFA – 308G > A, class switching to IgE by B cells (variants of IL-13 and of IL-4RA), and expression of IgE receptors on target cells (variant of the FcηRIβ gene). Delayed Tcell- mediated reactions are also associated with HLA alleles. Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity. HLA-B*5701 seems to be a strong predictor in whites, but not in Hispanics or Africans. Carbamazepine hypersensitivity is also influenced by gene variants of cytochrome P450 enzymes on the generation of reactive metabolites, while CYP2C9*2 and CYP2C9*3 polymorphisms influence the bioactivation of sulfamethoxazole in prohapten. Pharmacogenetic studies on aspirin hypersensitivity have identified distinct types of predictors, such as HLA genotypes, a polymorphism in the promoter of the FcηRIα gene, and variants in genes of enzymes from the arachidonic acid pathway. In the future, identification of genetic predictors will benefit from genomewide association studies that also take ethnic differences into account. Ideally, predictors will help to prevent adverse reactions, as suggested by a recent study on the effectiveness of prospective HLA-B* 5701 screening to prevent hypersensitivity reactions to abacavir in HIV patients.
Export Options
About this article
Cite this article as:
Gueant L. J., Gueant-Rodriguez M. R., Gastin Aimone I., Cornejo-Garcia A. J., Viola M., Barbaud A., Mertes M. P., Blanca M. and Romano A., Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity, Current Pharmaceutical Design 2008; 14 (27) . https://dx.doi.org/10.2174/138161208786369795
DOI https://dx.doi.org/10.2174/138161208786369795 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Mosquito Allergy and Mosquito Salivary Allergens
Protein & Peptide Letters Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Small Bowel: An Imaging Guide
Current Medical Imaging New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy